ASH 2023 | Gene therapy for SCD: unanswered questions
Rabi Hanna
• 11 Dec 2023
Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, discusses unanswered questions that remain around gene therapies for the treatment of sickle cell disease (SCD). He mentions expanding the application of these agents to more severe phenotypes, understanding long-term risks, and developing better conditioning regimens prior to treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: SOBI, Sanofi
Honoraria: Vertex
Research Funding: EDITAS
